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ABSTRACT 
 
The focus of this thesis is to describe the epidemiology of two causes of 
infectious diseases that are relevant to the Middle East and North Africa 
(MENA): arboviruses and gastrointestinal pathogens. Manuscript 1 is entitled 
“The Epidemiology of Dengue, Chikungunya, and Yellow Fever in the Middle 
East and North Africa: Systematic Review and Meta-Analysis.” In this work, we 
reviewed published records across the MENA region to describe the human 
prevalence, human incidence, and vector infection rates for dengue (DENV), 
chikungunya (CHIKV), and yellow fever (YFV) viruses. Through a systematic 
search, we identified 145 human prevalence measures for the study viruses in 
the MENA region: DENV (n=104), CHIKV (n=24), and YFV (n=17). 
Seroprevalence measures >20% were identified for DENV (range 0-60%) and 
CHIKV (range 0-42%) in the Red Sea region and Pakistan, while evidence for 
YFV infections was confined to Sudan. Meta-analyses across all studies in the 
MENA region estimated general population mean IgG seroprevalence for 
DENV at 8.6% (95% CI: 5.3-12.6%), CHIKV 4.3% (95% CI: 1.1-9.1%), and 
YFV 3.7% (95% CI: 0.2-10.4%). However, there was considerable 
heterogeneity in effect size as well as high variability in subregional study 
coverage, target study populations, and diagnostic methods among reported 
studies. This study provides a detailed characterization of the epidemiology of 
these arboviruses in the MENA while identifying current research gaps and 
priorities for future research. Manuscript 2 is entitled “Multiplex PCR for 
Detection of Gastrointestinal Pathogens in Migrant Workers in Qatar.” In this 
work, we conducted a prospective observational study to understand the 
clinical characteristics and infectious causes of diarrhea among migrant 
workers in Doha, Qatar. Seventy-five male workers coming to the Qatar Red 
Crescent Worker’s Health Center outpatient clinic or emergency department 
were enrolled in the study. Surveys were administered to all subjects and the 
prevalence of 23 different stool pathogens was determined by multiplex PCR 
(FilmArray® Gastrointestinal PCR). Salmonella was the most prevalent 
pathogen and was detected in 27% of all subjects, followed by 
enteropathogenic E. coli (21%), enteroaggregative E. coli (15%) and 
enterotoxigenic E. coli (12%). In a multivariable analysis, a triage heart rate ≥ 
90 beats per minute was the only significant predictor of a positive PCR result 
(OR 4.5, 95% CI 1.1-18.7). Use of multiplex PCR enabled the detection of 
gastrointestinal pathogens in 57% of cases overall, illustrating the utility of this 
diagnostic tool in epidemiologic studies of infectious diarrhea. 
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ABSTRACT 
 
The global distribution and disease burden of Aedes-borne arboviruses have 
increased in recent years. In the Middle East and North Africa (MENA) region, 
the epidemiology of dengue, chikungunya, and yellow fever remains poorly 
characterized. Following the PRISMA guidelines, we systematically reviewed 
available records across the MENA region describing the human prevalence, 
human incidence, and vector infection rates for dengue (DENV), chikungunya 
(CHIKV), and yellow fever (YFV) viruses. We synthesized the data in tables, 
maps, and meta-analyses estimating the region-specific prevalence for each 
virus in general populations and those with undifferentiated acute febrile 
illness (AFI) or ‘suspected’ dengue infection. In sum, we identified 145 human 
prevalence measures for the study viruses in the MENA region: DENV 
(n=104), CHIKV (n=24), and YFV (n=17). General and AFI-associated 
seroprevalence >20% was identified for DENV (range 0-60%) and CHIKV 
(range 0-42%) in the Red Sea region and Pakistan, while evidence for YFV 
infections was confined to Sudan. Meta-analyses across all studies in the 
MENA region estimated general population mean IgG seroprevalence for 
DENV at 8.6% (95% CI: 5.3-12.6%), CHIKV 4.3% (95% CI: 1.1-9.1%), and 
YFV 3.7% (95% CI: 0.2-10.4%). Among populations with AFI, mean 
prevalence estimates were DENV 18.6% (95% CI: 7.4-33.3%), CHIKV 8.8% 
(95% CI: 4.9-13.6%), and YFV 3.3% (95% CI: 0.0-22.4%). The meta-analyses 
identified considerable heterogeneity in effect size, and there was high 
variability in subregional study coverage, target study populations, and 
diagnostic methods among reported studies. Within the MENA region, 
available evidence suggests high DENV and CHIKV seroprevalence in the 
 4 
Red Sea region and Pakistan, while YFV is confined to Sudan. However, 
coverage is incomplete and available evidence demonstrates high clinical and 
methodological heterogeneity. These findings illustrate a challenge to defining 
the geographic distribution and infection pressures of these viruses in the 
region and indicate priorities for future research.  
 
INTRODUCTION 
 
Like much of the world, the Middle East and North Africa (MENA) is 
experiencing an apparent surge in the spread of Aedes-borne arboviruses [1-
6]. Over the past five years, reported dengue virus (DENV) infections reached 
unprecedented levels in the Arabian Peninsula and Pakistan [7, 8]. In 2011, 
local transmission of chikungunya virus (CHIKV) was recorded in the Arabian 
Peninsula for the first time during an outbreak in Yemen with over 15,000 
suspected cases [9]. The following year, Sudan experienced a yellow fever 
virus (YFV) outbreak that was declared one of the worst outbreaks the world 
had seen in recent history [10]. In November 2015, DENV re-emerged in 
Egypt after a decades-long absence of reported cases from the country [11]. 
Although only snapshots, these reports raise critical questions about the 
unmeasured burden and distribution of Aedes-borne arboviruses in the MENA 
region and the risk that Aedes-borne pathogens pose to the region in the 
future [12, 13].  
 
Still, gaining an understanding of the epidemiology of these viruses in the 
MENA region remains a challenge [14, 15]. Inadequate human and vector 
surveillance, non-reporting, and poor diagnostic capacity limit arbovirus 
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detection in many MENA countries, resulting in delays in outbreak recognition 
and sparse data with which to estimate disease burden and infection rates [9, 
12, 13]. In the absence of such capacity, differentiating between the various 
arboviral causes of acute febrile illness (AFI) by clinical grounds alone is often 
unreliable [9, 16-19], with reports of CHIK being mistaken for both YF [20] and 
DEN [9, 17], DEN being mistaken for Crimean-Congo Hemorrhagic Fever 
(CCHF) [21], and CCHF being mistaken for DEN [18, 19]. Even with laboratory 
capacity, the well-known cross-reactivity of flavivirus antibodies in serological 
diagnostic tests adds another layer of uncertainty to both clinical decision 
making and epidemiologic research [22, 23].  
To move beyond the uncertainties surrounding the epidemiology of Aedes-
borne arboviruses in the MENA, we present a comprehensive summary and 
appraisal of published prevalence, incidence, and outbreak data for DENV, 
CHIKV, and YFV in the region. These arboviruses were selected because of 
their putative emerging presence in the MENA and because of their shared 
mosquito vectors, Aedes aegypti and Aedes albopictus, which facilitate the 
potential for these viruses to have overlapping geographic distribution. 
Applying a systematic approach, we aimed to 1) provide an in-depth summary 
of the peer-reviewed literature detailing the prevalence and incidence of these 
viruses in humans, their infection rates in vectors, and reported human 
outbreaks, 2) summarize human prevalence data from a meta-analytic 
approach, and 3) describe epidemiologic knowledge gaps and areas at risk of 
Aedes-transmitted arboviruses. This report will enhance the understanding of 
the epidemiology of DENV, CHIKV, and YFV in the MENA and inform future 
research priorities 
 6 
MATERIALS AND METHODS 
Data Sources and Search Strategy. We conducted separate systematic 
reviews of the prevalence and incidence of DENV, CHIKV, and YFV in the 
MENA following the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [24]. The PRISMA checklist is found in 
S1 Figure and our search criteria in S2 Figure. Briefly, we searched PubMed, 
Embase, the World Health Organization (WHO) Index Medicus for the Eastern 
Mediterranean Region (EMRO) and WHO African Index Medicus (AIM) (up to 
December 9, 2015) using separate search criteria for each virus without 
publication date or language restrictions, using text and MeSH/Emtree terms 
exploded to include all subheadings. Our review covered the 23 countries 
included in the MENA definitions of the WHO/EMRO, World Bank, and the 
Joint United Nations Programme on HIV/AIDS (UNAIDS) for consistency with 
earlier regional analyses of various infections diseases including HIV (S3 
Figure)[25].  
 
Study Selection. For each study virus, titles and abstracts were imported into 
Endnote (Thompson Reuters, Philadelphia, PA, USA), duplicates removed, 
and screened by one author (JH) with potential eligibility determined by 
consensus with a second author (NC) when necessary. Full texts of potentially 
relevant records were retrieved and assessed for eligibility. Reference lists of 
all potentially eligible articles and reviews were also searched. Studies 
containing primary prevalence or incidence data pertaining to at least one of 
the study viruses in the MENA region were considered eligible for the 
systematic review (Figure 1.1). Case reports, case series, editorials, letters to 
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editors, reviews, commentaries, qualitative studies, basic science research 
studies, and studies from countries outside the region were excluded from the 
systematic review. One YFV seroprevalence study conducted among YFV 
vaccine recipients was also excluded from the YFV review given the inability to 
differentiate wild and vaccine-derived antibodies [26]). In our study, the term 
‘report’ refers to the document (paper, abstract, or public health record) 
containing an outcome measure of interest, while ‘study’ refers to the outcome 
measure(s) within that report. Hence, reports could contribute more than one 
study, although multiple reports of the same study were counted only once. 
Outbreak reports were identified through a separate search using the same 
search criteria. Outbreaks were defined by the author’s description of the 
event as an outbreak. Multiple reports of the same outbreak were counted only 
once.  
 
 
 
 
 
 
 
 
 
 
 
 
 8 
Figure 1.1 PRISMA flow diagrams of article selection 
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Data Extraction and Synthesis. Data were extracted by one of the authors 
(JH) using a pre-piloted data extraction form and entered into a database 
created in Microsoft Access. Data from reports in English were extracted from 
the full texts, while reports in French (n=3), Turkish (n=3) and German (n=1) 
were extracted from the English abstract and with the help of online language 
software [27]. There were no records in other languages. The list of extracted 
information is located in S4 Figure. For each virus, studies were synthesized 
by country and organized by year, using separate tables for human and animal 
prevalence and vector infection rates (i.e. the estimated proportion of infected 
mosquitoes in a population at a given time). Human prevalence studies were 
further separated into three groups: general seroprevalence studies, 
undifferentiated acute febrile illness (AFI) studies, and studies of ‘suspected’ 
dengue infection. The definitions for these populations are found in S5 Figure. 
We also appraised the quality of the general population and AFI population 
prevalence measures by assessing the risk of bias (ROB) for each study using 
an adaptation of the Cochrane approach and by evaluating the precision of the 
reported measures [28]. A description of the quality assessment criteria and 
ROB assessment is found in S6 Figure. Finally, we mapped the geographic 
distribution of all human prevalence studies and at the level of the 
province/governorate in the MENA region (Tableau Software, Seattle, WA, 
USA). We manually marked the location of reported outbreaks on these maps 
as well, designating one mark per province in which one or more outbreaks 
were reported.  
 
Quantitative analysis. Meta-analyses of human prevalence studies among 
general populations were conducted for each virus using the most specific IgG 
 11 
serologic measure reported for each study (e.g. viral neutralization test (VNT) 
rather than ELISA, when available). Meta-analyses of the seroprevalence 
among populations with acute undifferentiated febrile illness (AFI) populations 
were also conducted for each virus, utilizing baseline IgG seroprevalence 
measures for the study population, which were more likely indicative of 
secondary, rather than primary, infection. Studies that did not include baseline 
IgG seroprevalence measures, including studies of ‘suspected’ dengue 
infection and some AFI studies, were not included in this analysis.  
 
The variance of the prevalence measures was stabilized using the Freeman-
Tukey type arcsine square-root transformation [29]. Prevalence estimates 
were weighed using the inverse variance method and then pooled using a 
DerSimonian-Laird random effects model [30]. This model assumes a normal 
distribution of true effect sizes across studies, and therefore accounts for the 
sampling variation as well as the heterogeneity in effect size [31]. The I2 
heterogeneity measure and its confidence interval (CI) were calculated to 
assess the magnitude of between-study variation that is due to differences in 
effect size across studies rather than chance [32]. Other heterogeneity 
measures were also calculated, including Cochran’s Q statistic to test for 
heterogeneity in effect size, 2  to estimate the between-study variance of the 
true effect size, and prediction intervals to estimate the 95% interval in which 
the true effect size in a new study will lie [31, 33]. 
 
Finally, a meta-regression was performed to identify between-study 
heterogeneity in the pooled mean general population prevalence estimates for 
DENV [28, 34]. The following covariates were examined in univariable and 
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multivariable models: country, year of study, assay type (ELISA, complement 
fixation, hemagluttinin inhibition, immunoflouresence antibody test, or viral 
neutralization titer), sampling method, and the precision of the measure (i.e. 
≥100 participants). These covariates were included in the multivariable model 
if the p-value was <0.1. 
 
RESULTS 
 
Search Results. The selection processes based on PRISMA guidelines are 
illustrated for each of the study viruses in Figure 1.1 [24]. Briefly, the DENV 
search yielded 1,258 citations, 90 of which were ultimately eligible for inclusion 
in the study with the addition of 4 reports identified from the bibliographies of 
relevant reports and reviews. The CHIKV search yielded 179 citations, 23 of 
which were eligible for inclusion in the study following screening process and 
after the addition of 8 reports. For YFV, 1,105 citations were retrieved through 
a separate search, 18 of which were eligible following the screening process 
and with the addition of 3 external reports.   
 
Dengue Overview. A total of 104 human prevalence studies for DENV were 
identified from eligible reports (Table 1.1). These studies covered 13 of 24 
MENA countries and were conducted from 1962-2015. The geographic 
distribution of these studies is illustrated in Figure 1.2. Anti-DENV antibodies 
were reported from 12 of 13 countries in which studies were reported with a 
single 1973 study from Libya reporting 0% seroprevalence [35]. The highest 
number of studies were reported from Pakistan (n=30) and Sudan (n=16), 
most of which targeted populations with AFI or those with suspected dengue 
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infection (Table 1.1). Among general populations, IgG prevalence measures 
ranged from 0% to 61% and were reported from Djibouti (n=4, 0-21%), Egypt 
(n=4, 0-7%), Iran (n=3, 0-7%), Kuwait (n=3, 0-56%), Lebanon (n=3, 0-61%), 
Pakistan (n=3, 9-28%), Saudi Arabia (n=4, 0-33%), and Sudan (n=5, 9-49%). 
However, observed or potential serologic cross-reactions with other 
flaviviruses were present in multiple studies, while the results of VNT were 
reported in 3% (n=3) of studies [26, 36, 37]. Three human incidence measures 
for DENV were identified (S1 Table); the first reported an ELISA IgM incidence 
of 35 cases per 10,000 people living in urban homes where DENV-carrying 
mosquitoes were identified [38]; the second reported an ELISA IgM incidence 
of 94 cases per 10,000 people among a general population in Port Sudan, 
Sudan over a 17 week period in 2010 [39]; the third reported an ELISA IgM, 
NS1 antigen, or PCR incidence of 18 cases per 10,000 people among febrile 
children in an urban slum in Karachi, Pakistan from 1999-2001 [40]. Four 
reports containing DENV seroprevalence measures in animals from the 1970-
80s were identified from Pakistan, Tunisia, and Turkey but may also have 
represented cross-reactions with other flaviviruses (S2 Table) [41-44]. Two 
reports containing DENV infection rates in A. aegypti populations were 
identified in Pakistan and Yemen, respectively (S3 Table). 
 14 
Table 1.1 Summary of human prevalence studies for dengue virus in the 
Middle East and North Africa (n=104). 
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Figure 1.2 Geographic distribution of human prevalence studies and reported 
outbreaks for dengue, chikungunya, and yellow fever viruses  
in the Middle East and North Africa. 
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Chikungunya Overview. A total of 24 human seroprevalence studies for 
CHIKV were identified from eligible reports, 72% of which were conducted 
prior to 1990 (Table 1.2). Figure 1.2 illustrates the geographic distribution of 
CHIKV prevalence studies in the MENA region. Overall, Sudan reported both 
the highest number of human seroprevalence studies (n=8) and the highest 
general population seroprevalence (range 12-43%) in the region. High 
seroprevalence among febrile patients was identified in Yemen, in which three 
studies following identification of a CHIK outbreak reported ELISA IgM or RT-
PCR prevalence among febrile patients of 9-28% [116-118]. Additional positive 
general or AFI seroprevalence measures were reported from Djibouti, Egypt, 
Iran, Kuwait, and Pakistan. However, serologic cross-reactions with related 
alphaviruses (O’nyong-nyong, Sandfly Fever, and Sindbis viruses) or travel-
acquired infections were observed or could not be excluded in some studies 
from Djibouti [46], Iran [52], Kuwait [56, 120], and Pakistan [41]. VNT were 
utilized in a total of three studies from Djibouti [48] and Sudan [36, 121], 
confirming the presence of anti-CHIKV antibodies in general popoulations in 
both countries. Two reports assessing CHIKV seroprevalence in various 
animal species were identified, although all detected antibodies were found to 
be cross-reactive with SINV (S2 Table) [41]. One report of CHIKV infection 
rates in A. aegypti mosquitoes was identified in our search, in which 26% 
CHIKV prevalence was detected during a CHIKV outbreak in Yemen (S3 
Table)[122]. No human incidence reports were identified. 
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Table 1.2 Summary of human prevalence studies for chikungunya virus in the 
Middle East and North Africa (n=24).  
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Yellow Fever Overview. A total of 17 seroprevalence studies conducted from 
1952-2011 were identified from eligible reports for YFV (Table 1.3). The 
geographic distribution of all YFV prevalence studies are illustrated in Figure 
1.2. Anti-YFV antibodies were reported from populations in Djibouti, Lebanon, 
Somalia, Sudan, and Turkey. Neutralization testing or other 
secondary/confirmatory testing was performed in 7 (41%) studies, supporting 
the presence of anti-YFV antibodies in populations in Djibouti and Sudan but 
not in Turkey. Two reports containing seroprevalence measures for various 
animal species in Sudan were also identified (S2 Table), and there were no 
reports of YFV human incidence or vector infection rates identified from the 
region. 
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Table 1.3 Summary of human prevalence studies for yellow fever virus in the 
Middle East and North Africa 
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Overview of Outbreaks. Reported outbreaks of DENV, CHIKV, and YFV in 
the region were gathered through citations collected from the search 
databases (S4 Table) and mapped along with the geographic distribution of 
prevalence studies in Figure 1.2. For DENV, 81 outbreaks were reported from 
9 countries in the region from 1941-2015, including sentinel reports of 
autochthonous transmission in Egypt (2010), and Yemen (1983). For CHIKV, 
4 outbreaks were reported from Djibouti, Sudan, and Yemen, along with a 
sentinel report of autochthonous transmission in Saudi Arabia (2011). For 
YFV, 6 outbreak reports were identified, all recorded in Sudan from 1940-
2013.  
 
Pooled mean prevalence estimates for Dengue, Chikungunya, and 
Yellow Fever. The results of the pooled IgG seroprevalence estimates for 
both general and AFI populations are summarized in Table 1.4. The pooled 
IgG seroprevalence estimates among general populations in the MENA region 
were: DENV 8.6% (95% CI: 5.3-12.6%), CHIKV 4.3% (95% CI: 1.1-9.1%), and 
YFV 3.7% (95% CI: 0.2-10.4%). Among AFI populations, higher pooled 
prevalence estimates were estimated as follows: DENV 18.6% (95% CI: 7.4-
33.3%), CHIKV 8.8% (95% CI: 4.9-13.6%), and YFV 3.3% (95% CI: 0.0-
22.4%). The forest plots for each of these meta-analyses can be found in S7-
S12 Figures. There was substantial evidence for heterogeneity in effect size in 
all meta-analyses, with p-value always <0.0001. Variation in effect size, rather 
than chance, accounted for the majority of the variation in all meta-analyses (I2 
>60%). The prediction intervals for each of these studies were broad, also 
highlighting substantial heterogeneity in effect size across studies. 
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Table 1.4 Pooled mean estimates for dengue, chikungunya, and yellow fever IgG 
seroprevalence stratified by general population and populations with undifferentiated 
acute febrile illness (AFI)  
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A multivariable meta-regression for DENV general and AFI population 
prevalence measures identified assay type as the only statistically significant 
prevalence-modifiable factor when adjusted for country, year of study, study 
precision, and sampling method. Hemagluttinin inhibition and 
immunoflouresence antibody tests were significantly more likely to yield lower 
prevalence values than ELISA or complement fixation tests. There was not 
sufficient statistical power to assess the effect size contribution of viral 
neutralization testing since there was only one prevalence measure using this 
assay type. Given the smaller number of prevalence studies for CHIKV and 
YFV general and AFI populations, we did not conduct meta-regressions to 
explore between-study heterogeneity in the pooled mean prevalence 
estimates for these viruses. 
 
Quality Assessment. A summary of the precision and risk of bias 
assessment for human seroprevalence studies for each of the study viruses is 
located in S5 Table. The quality assessment for each study can be found in 
S6-S11 Tables. In brief, most studies (62-76%) contained high precision as 
defined by a sample size of ≥100 participants. Approximately 80% of studies in 
all categories utilized convenience samples and over 90% did not report 
response rates, entailing high and unclear ROB, respectively.  
 
DISCUSSION 
 
Our study offers the first systematic assessment of the current knowledge on 
the epidemiology of dengue, chikungunya, and yellow fever viruses in the 
MENA region from the standpoint of published prevalence and incidence data 
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and outbreak reports from the region. The results of our study indicate two 
apparent risk zones in the MENA harboring substantial circulation of Aedes-
borne viruses: 1) Pakistan and 2) the Red Sea subregion. No human 
seroprevalence data was identified across broad subregions of the MENA, 
however, including some Aedes endemic areas. Moreover, our study identified 
a paucity of reports estimating human incidence and vector infection rates in 
the region. These limitations, along with the high study diversity and statistical 
heterogeneity identified in the meta-analyses of seroprevalence studies, 
simultaneously challenge efforts to synthesize and compare the inter- and 
intra-country epidemiology of the study viruses in the region while also 
revealing priorities for future research. 
 
Dengue, Chikungunya, and Yellow Fever in the MENA region 
 
Dengue virus. DENV is a globally distributed flavivirus that has a historic 
presence in the MENA region, with outbreaks of DENV and DENV-like disease 
reported across much of the Eastern Mediterranean region in the 19th and 
early 20th century [58, 129]. Our study demonstrates the presence of DENV 
focusing in two areas of the MENA: Pakistan and the Red Sea region. 
Pakistan demonstrated the highest number of reported prevalence studies and 
the broadest study coverage among MENA countries, suggesting substantial 
infection pressures in the country. Multiple studies reported >20% prevalence 
in both general population and those with AFI in the country [107, 130-133], 
and unlike other MENA countries, DENV serotypes 1-4 are all known to 
circulate in Pakistan [83]. Moreover, Pakistan reported the largest number of 
 35 
confirmed cases among the DENV outbreaks in the MENA, with 21,580 cases 
reported during the 2011 outbreak of DENV-2 [80, 134] (S4 Table).  
 
In the Red Sea region, our study identified multiple general population IgG 
seroprevalence measures and/or IgG seroprevalence measures among 
populations with AFI exceeding 20% in Djibouti, Saudi Arabia, Somalia, 
Sudan, and Yemen within the past decade (Table 1.1) along with multiple 
confirmed outbreaks of DENV serotypes 1-3 since the 1980s (S4 Table). 
Notably, the presence of DENV-4 has not yet been identified in this subregion 
to our knowledge. Although most reported outbreaks localize along the Red 
Sea coastline in these countries, seroprevalence studies suggest a broader 
distribution of DENV infections that are likely undetected throughout the 
subregion (Figure 1.2). This historic underdetection is also illustrated by the 
report of a traveler diagnosed with dengue after returning from Yemen in 1983 
[135], followed by the first detected outbreaks of DENV in Yemen and Saudi 
Arabia 11 years later in 1994 [136-138]. In Egypt, our search identified no 
published prevalence studies or outbreaks after 1969 until a DEN outbreak 
was reported in November 2015 [11]. However, DENV transmission was 
suggested years beforehand by a report of two travelers diagnosed with DEN 
after returning from southern Egypt in 2011 [139] and the identification of A. 
aegypti in southern Egypt that same year [140]. Hence, whether the 
increasingly reported outbreaks from the region represent increasing 
incidence, increasing detection, or both, is not clearly defined amidst the high 
heterogeneity in study coverage and reporting across time and space in the 
MENA region (further described below). 
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Chikungunya virus.  Chikungunya virus has traced the epidemiology of 
DENV in recent years to also establish itself as a global pathogen [130]. The 
past decade, CHIKV was implicated in an Indian Ocean outbreak with over a 
million cases, novel autochthonous transmission in Mediterranean Europe in 
2007, and in 2013, novel transmission throughout the Caribbean islands and 
Latin America [141-146]. In our study, serologic evidence of CHIKV 
transmission in the MENA region has been published since the 1970s [9, 36, 
41, 52, 116]. Like DENV, published seroprevalence studies and outbreaks 
appear to localize to the Red Sea region and Pakistan (Figure 1.2), with IgG 
seroprevalence in general populations and those with AFI measured over 20% 
in both Sudan and Yemen and 2% in Djibouti and Pakistan (Table 1.2). 
However, unlike DENV, confirmation of CHIKV in the MENA region was not 
published until 2010 during an outbreak in Yemen with over 15,000 suspected 
cases [116, 147]. This, along with the overall paucity of CHIKV prevalence 
studies and outbreak reports identified in our study, suggests a potentially 
substantial underrecognition of CHIKV in the MENA.  
 
Yellow Fever virus.  In the MENA region, YFV outbreaks have remained 
limited to Sudan, which lies within the Yellow Fever Belt of Africa (and S4 
Table). Sporadic epidemics have been recorded in the country since 1940, 
primarily centered in the Nuba Mountain region in the south of the country [10, 
128, 148]. Yet despite the longstanding availability of an effective vaccine, 
outbreaks of yellow fever were recently detected in South Kordofan and Darfur 
in 2005 and 2012, respectively [10, 148]. Moreover, seroprevalence studies 
have indicated widespread seroprevalence throughout the country (Table 1,3), 
though some measures raise the possibility of cross-reactions with other 
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flaviviruses or detection of vaccine-derived antibodies [37, 48, 50, 58, 113, 
127]. Still, risk of YFV introduction must be considered for countries outside of 
Somalia and Sudan, particularly in A. aegypti endemic areas of Djibouti, 
Yemen, and Saudi Arabia [21]. 
 
Study Diversity and Limitations. An important finding our study was the 
substantial clinical and methodological diversity encountered among 
prevalence studies and in the meta-analyses for each virus. Clinically, studies 
represented a diversity of human populations of different ages and 
demographics, in different years, and in different locations and transmission 
contexts. A high proportion of studies were conducted decades ago when less 
stringent study methodologies or reporting standards may have been more 
common. This was also reflected in the assays utilized, with multiple studies 
utilizing assays susceptible to serologic cross-reactions and few utilizing 
confirmatory testing such as VNT. The meta-regression for DENV studies 
identified assay type as a statistically significant prevalence modifying factor. 
However, caution must be taken in interpreting the significance of this finding 
given the number of potentially prevalence-modifying covariates not included 
in the analysis, such as participant demographics or study context. 
Methodologically, most studies utilized convenience samples without reporting 
response rates, entailing the risk of bias and uncertainty in the accuracy of 
reported measure (S5 Table).  
 
Meta-analyses for general populations and populations with AFI also 
demonstrated high statistical heterogeneity in effect size in all subgroups with 
wide prediction intervals (26-96%), entailing high uncertainty for the effect 
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estimates generated. Such statistical heterogeneity was expected given the 
apparent clinical and methodological diversity and wide rage of reported 
prevalence values. Nevertheless, this heterogeneity represents a challenge to 
interpreting the body of prevalence data that currently exists in the MENA.  
 
Risk Assessment and Research Priorities. Our study did not identify any 
evidence confirming autochthonous transmission of DENV, CHIKV, or YFV in 
any of the MENA countries West of Egypt and East of Saudi Arabia until 
Pakistan (Figure 1.2). However, the paucity of published epidemiologic data in 
these sub-regions does not preclude the possibility of unrecognized 
transmission in some areas or the risk of emergence in others. Indeed, 
modeling studies suggest ecologic niches for Aedes along the coastal 
Mediterranean Basin of North Africa [131, 132, 149], and the presence of A. 
albopictus has been recently reported in Algeria, Lebanon, Palestine, Syria, 
and Turkey [58, 150-154]. In contrast, A. albopictus has been identified along 
the Mediterranean coast of Europe for decades, and local transmission of 
CHIKV in Italy and France and DENV in France and Croatia has been 
identified since 2007 [155]. Near the Pakistan border, seroprevalence studies 
also suggest the possibility of DENV transmission in Iran [13, 52, 54] and 
Afghanistan [45], though confirmatory investigations in these regions have not 
been published to our knowledge [54]. Given the limited human and vector 
surveillance in these regions, the presence of A. aegypti or A. albopictus, or 
the possibility of unrecognized dengue transmission, cannot be ruled out [54].  
 
Moreover, the MENA region exhibits a variety of ecologic and social factors 
that may promote the spread of Aedes-borne viruses. Increased urbanization 
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in the region [156] promotes population crowding that augments the risk of 
outbreaks and, in some areas, use of open water storage containers that 
promote A. aegypti breeding [38, 56, 96, 111, 122, 131, 132, 149]. Unusually 
heavy rainfall or flooding has been implicated as an inciting factor in multiple 
DENV outbreaks in Sudan, Djibouti, and Yemen [9, 48, 157, 158], phenomena 
which may grow increasingly unpredictable as climate change affects the 
region. Armed conflicts and economic turmoil, as that which has occurred in 
Yemen, Syria, and Iraq, may render previously stable communities vulnerable 
to vector-borne disease transmission while further disabling public health 
surveillance and outbreak response capacity [159]. Inter-regional migration 
pose risk for imported arboviruses as well, as millions of migrants travel from 
DENV and CHIKV endemic countries in Asia and North Africa to the Arabian 
Peninsula to work [111, 136, 147, 159-161] and millions more travel annually 
to Mecca, Saudi Arabia (a DENV endemic region) to attend the Umra and Hajj 
[136]. Intra-regionally, heavy human travel and trade in the Red Sea region 
likely drives arbovirus mixing and spread [116, 161], as evidenced by multiple 
DENV outbreaks occurring at Red Sea port cities in Djibouti [37, 46], Sudan 
[38] Yemen [116, 161], and Saudi Arabia [136]. Risk of contiguous spread of 
DENV from Yemen to Oman [162] or from Pakistan to Iran or Afghanistan [13] 
has been raised.  
 
The results of our study emphasize the need for further research into the 
prevalence and distribution of Aedes-borne arboviruses in the MENA region. 
Our study was limited by its reliance on select databases of peer-reviewed 
literature with the exclusion of grey literature which may have provided 
additional data. In addition, including other Aedes-transmitted pathogens or 
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studies reporting Aedes distribution in the MENA may have provided further 
insights regarding the geographic distribution of the study viruses. 
Nevertheless, a number of research priorities emerge concerning these 
pathogens in the MENA.  
 
First, broader seroepidemiologic survey coverage in the region is needed. 
Such studies are efficient means of characterizing infection pressures in 
populations lacking public health surveillance and diagnostic capacity, 
particularly when transmission status is uncertain. Multiplexed diagnostics are 
increasingly available for such purposes and are well-suited for simultaneously 
exploring the possible distribution of a number of other undercharacterized 
arboviruses in the region (e.g. Alkhumra, Crimean-Congo Hemorrhagic Fever, 
O’Nyong-nyong, Rift Valley Fever, Sandfly Fever virus complex, Usutu, West 
Nile viruses). Second, future seroprevalence studies include methods to 
minimize serologic cross-reactions whenever possible, particularly for the 
flavivirus serocomplexes [163]. Third, seroepidemiologic studies should 
incorporate uniformity in study design and enrollment criteria to minimize 
confounding, such as the standard case definitions or for studies of 
‘suspected’ dengue infection put forth by the WHO [164]. Ideally this could 
include population-based sampling studies, which could provide baseline data 
from which to benchmark the impact of these pathogens in the region over the 
coming years. Fourth, future studies should incorporate vector surveillance 
and studies of infection rates, as our study identified a paucity of vector 
infection rates in the MENA. Such studies are important for understanding 
transmission dynamics that inform vector control strategies, predict future 
transmission activity, and project disease risk to humans [131, 149, 155]. 
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Guidelines and standard tools for calculating vector infection rates are 
available [155, 165].  
 
Our study provides a comprehensive systematic summary of the evidence 
supporting the epidemiology of dengue, chikungunya, and yellow fever in the 
MENA region. The available seroprevalence and outbreak data clearly 
suggests the Red Sea region and Pakistan are transmission zones for DENV 
and CHIKV in the MENA, while YFV remains confined to Sudan. However, 
high study diversity and statistical heterogeneity exists among studies and 
broad areas lack published data, particularly concerning incidence rates and 
vector infection rates in the MENA. These findings serve as a resource for 
future arbovirus research planning in the MENA by articulating epidemiologic 
knowledge gaps and the need for well-designed seroepidemiologic and vector 
studies. Such studies are essential to assess and mitigate the impact of 
arbovirus disease in the MENA region.  
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S2 Figure Data sources and search criteria used for the systematic review of 
dengue, chikungunya, and yellow fever virus prevalence and incidence in the 
Middle East and North Africa.  
Dengue Search Criteria 
PubMed (Last searched December 9, 2015) 
 
("Dengue"[text] OR "Dengue"[mesh] OR "Dengue Virus"[mesh] OR “Aden fever”[text] or 
“bouquet fever”[text] or “breakbone fever”[text] or “dandy fever”[text] or “red fever”[text] or 
“solar fever”[text] or “sun fever”[text] OR Flavivir*[text] OR “Arbovirus, Group B”[Mesh]) 
AND ("Middle East"[Mesh] OR "Islam"[Mesh] OR "Arabs"[Mesh] OR "Arab World"[Mesh] 
OR "Africa, Northern"[Mesh] OR "Sudan"[Mesh] OR "Somalia"[Mesh] OR 
"Djibouti"[Mesh] OR "Pakistan"[Mesh] OR "Middle East"[Text] OR "Middle-East"[Text] OR 
"North Africa"[Text] OR "North-Africa"[Text] OR "EMRO"[Text] OR "Eastern 
Mediterranean"[Text] OR “Arab”[Text] OR “Arabs”[Text] OR “Arab World”[Text] OR 
"Islam"[Text] OR "Afghanistan"[Text] OR "Algeria"[Text] OR "Bahrain"[Text] OR 
"Djibouti"[Text] OR "Egypt"[Text] OR "Jordan"[Text] OR "Kuwait"[Text] OR 
"Lebanon"[Text] OR "Libya"[Text] OR "Iran"[Text] OR "Iraq"[Text] OR "Morocco"[Text] 
OR "Oman"[Text] OR "Pakistan"[Text] OR "Qatar"[Text] OR "Saudi Arabia"[Text] OR 
"Somalia"[Text] OR "Sudan"[Text] OR "Syria"[Text] OR "Tunisia"[Text] OR “Turkey”[text] 
OR "United Arab Emirates"[Text] OR "Dubai"[Text] OR "Abu Dhabi"[Text] OR "Abu-
Dhabi"[Text] OR “Sharjah”[Text] OR "West Bank"[Text] OR "Ghaza"[Text] OR 
"Palestine"[Text] OR"Yemen"[Text]) 
 
Embase (Embase 1974 to 2015 Week 49; Last searched December 9, 2015) 
 
(exp Dengue/ OR Dengue.mp OR Aden Fever.mp OR Bouquet Fever.mp OR Breakbone 
Fever.mp OR Dandy Fever.mp OR Red Fever.mp OR Solar Fever.mp OR Sun Fever.mp 
OR Flavivir*.mp OR Arbovirus, Group B.mp.) AND (exp Middle East/ or exp North Africa/ 
or exp Arab/ or exp Afghanistan/ or exp Djibouti/ or exp Pakistan/ or exp Somalia/ or exp 
Sudan/ or Middle East.mp. or North Africa.mp. or EMRO.mp. or Eastern 
Mediterranean.mp. or Arab.mp. or Arabs.mp. or Arab World.mp. or Islam.mp. or 
Afghanistan.mp. or Algeria.mp. or Bahrain.mp. or Djibouti.mp. or Egypt.mp. or 
Jordan.mp. or Kuwait.mp. or Lebanon.mp. or Libya.mp. or Iran.mp. or Iraq.mp. or 
Morocco.mp. or Oman.mp. or Pakistan.mp. or Qatar.mp. or Saudi Arabia.mp. or 
Somalia.mp. or Sudan.mp. or Syria.mp. or Tunisia.mp. or Turkey.mp or United Arab 
Emirates.mp. or Dubai.mp. or Abu Dhabi.mp. or Sharjah.mp. or West Bank.mp. or 
Ghaza.mp. or Palestine.mp. or Yemen.mp.) 
 
Chikungunya Search Criteria 
PubMed (Last searched December 9, 2015) 
 
("Chikungunya"[text] OR "Chikungunya Virus"[mesh] OR “CHIK”[text] OR Alphavir*[text] 
OR “Arbovirus, Group A”[Mesh]) AND ("Middle East"[Mesh] OR "Islam"[Mesh] OR 
"Arabs"[Mesh] OR "Arab World"[Mesh] OR "Africa, Northern"[Mesh] OR "Sudan"[Mesh] 
OR "Somalia"[Mesh] OR "Djibouti"[Mesh] OR "Pakistan"[Mesh] OR "Middle East"[Text] 
OR "Middle-East"[Text] OR "North Africa"[Text] OR "North-Africa"[Text] OR 
"EMRO"[Text] OR "Eastern Mediterranean"[Text] OR “Arab”[Text] OR “Arabs”[Text] OR 
“Arab World”[Text] OR "Islam"[Text] OR "Afghanistan"[Text] OR "Algeria"[Text] OR 
"Bahrain"[Text] OR "Djibouti"[Text] OR "Egypt"[Text] OR "Jordan"[Text] OR 
"Kuwait"[Text] OR "Lebanon"[Text] OR "Libya"[Text] OR "Iran"[Text] OR "Iraq"[Text] OR 
"Morocco"[Text] OR "Oman"[Text] OR "Pakistan"[Text] OR "Qatar"[Text] OR "Saudi 
Arabia"[Text] OR "Somalia"[Text] OR "Sudan"[Text] OR "Syria"[Text] OR "Tunisia"[Text]  
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S2 Figure Continued 
Embase (Embase 1974 to 2015 Week 49; Last searched December 9, 2015) 
 
(exp Chikungunya/ OR exp Chikungunya virus/ OR Chikungunya.mp OR CHIK.mp OR 
Alphavir*.mp or group A arbovirus.mp) AND (exp Middle East/ or exp North Africa/ or exp 
Arab/ or exp Afghanistan/ or exp Djibouti/ or exp Pakistan/ or exp Somalia/ or exp Sudan/ 
or Middle East.mp. or North Africa.mp. or EMRO.mp. or Eastern Mediterranean.mp. or 
Arab.mp. or Arabs.mp. or Arab World.mp. or Islam.mp. or Afghanistan.mp. or Algeria.mp. 
or Bahrain.mp. or Djibouti.mp. or Egypt.mp. or Jordan.mp. or Kuwait.mp. or Lebanon.mp. 
or Libya.mp. or Iran.mp. or Iraq.mp. or Morocco.mp. or Oman.mp. or Pakistan.mp. or 
Qatar.mp. or Saudi Arabia.mp. or Somalia.mp. or Sudan.mp. or Syria.mp. or Tunisia.mp. 
or Turkey.mp or United Arab Emirates.mp. or Dubai.mp. or Abu Dhabi.mp. or 
Sharjah.mp. or West Bank.mp. or Ghaza.mp. or Palestine.mp. or Yemen.mp.) 
 
Yellow Fever Search Criteria 
PubMed (Last searched December 9, 2015) 
 
("Yellow Fever"[text] OR “YF”[text] OR "Yellow Fever Virus"[Mesh] OR "Yellow 
Fever"[Mesh] OR Flavivir*[text] OR “Arbovirus, Group B”[Mesh]) AND ("Middle 
East"[Mesh] OR "Islam"[Mesh] OR "Arabs"[Mesh] OR "Arab World"[Mesh] OR "Africa, 
Northern"[Mesh] OR "Sudan"[Mesh] OR "Somalia"[Mesh] OR "Djibouti"[Mesh] OR 
"Pakistan"[Mesh] OR "Middle East"[Text] OR "Middle-East"[Text] OR "North Africa"[Text] 
OR "North-Africa"[Text] OR "EMRO"[Text] OR "Eastern Mediterranean"[Text] OR 
“Arab”[Text] OR “Arabs”[Text] OR “Arab World”[Text] OR "Islam"[Text] OR 
"Afghanistan"[Text] OR "Algeria"[Text] OR "Bahrain"[Text] OR "Djibouti"[Text] OR 
"Egypt"[Text] OR "Jordan"[Text] OR "Kuwait"[Text] OR "Lebanon"[Text] OR "Libya"[Text] 
OR "Iran"[Text] OR "Iraq"[Text] OR "Morocco"[Text] OR "Oman"[Text] OR 
"Pakistan"[Text] OR "Qatar"[Text] OR "Saudi Arabia"[Text] OR "Somalia"[Text] OR 
"Sudan"[Text] OR "Syria"[Text] OR "Tunisia"[Text] OR “Turkey”[text] OR "United Arab 
Emirates"[Text] OR "Dubai"[Text] OR "Abu Dhabi"[Text] OR "Abu-Dhabi"[Text] OR 
“Sharjah”[Text] OR "West Bank"[Text] OR "Ghaza"[Text] OR "Palestine"[Text] 
OR"Yemen"[Text]) 
 
Embase (Embase 1974 to 2015 Week 49; Last searched December 9, 2015) 
 
(exp Chikungunya/ OR exp Chikungunya virus/ OR Chikungunya.mp OR CHIK.mp OR 
Alphavir*.mp or group A arbovirus.mp) AND (exp Middle East/ or exp North Africa/ or exp 
Arab/ or exp Afghanistan/ or exp Djibouti/ or exp Pakistan/ or exp Somalia/ or exp Sudan/ 
or Middle East.mp. or North Africa.mp. or EMRO.mp. or Eastern Mediterranean.mp. or 
Arab.mp. or Arabs.mp. or Arab World.mp. or Islam.mp. or Afghanistan.mp. or Algeria.mp. 
or Bahrain.mp. or Djibouti.mp. or Egypt.mp. or Jordan.mp. or Kuwait.mp. or Lebanon.mp. 
or Libya.mp. or Iran.mp. or Iraq.mp. or Morocco.mp. or Oman.mp. or Pakistan.mp. or 
Qatar.mp. or Saudi Arabia.mp. or Somalia.mp. or Sudan.mp. or Syria.mp. or Tunisia.mp. 
or Turkey.mp or United Arab Emirates.mp. or Dubai.mp. or Abu Dhabi.mp. or 
Sharjah.mp. or West Bank.mp. or Ghaza.mp. or Palestine.mp. or Yemen.mp.) 
 
Regional Databases 
Index Medicus for the Eastern Mediterranean Region and African Index Medicus 
(Last searched December 9, 2015) 
 
separate searches were conducted using the terms ‘dengue’, ‘chikungunya’, and ‘yellow 
fever’ OR “Turkey”[text] OR "United Arab Emirates"[Text] OR "Dubai"[Text] OR "Abu 
Dhabi"[Text] OR "Abu-Dhabi"[Text] OR “Sharjah”[Text] OR "West Bank"[Text] OR 
"Ghaza"[Text] OR "Palestine"[Text] OR "Yemen"[Text]) 
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S4 Figure Lists of variables extracted from relevant reports for dengue 
(DENV), chikungunya (CHIKV), and yellow fever (YFV) virus incidence and/or 
prevalence studies. 
 
Extraction variable Description 
Author  
Full citation  
Country of survey  
Year(s) of data collection  *year of publication when data collection period not reported 
Duration of data collection for incidence studies only 
City or Governorate  
Study setting  
Study population  including population age range in years, when available 
Sampling method  
Assay type  complement fixation (CF) test, enzyme-linked immunosorbent 
assay (ELISA) IgG and IgM, immunofluorescence antibody 
assay (IFA), hemagluttinin inhibition (HI), NS1 antigen test, 
viral neutralization test (VNT), polymerase chain reaction 
(PCR), cell culture 
Assay make in-house or commercial, and name of commercial assay 
when available 
Target protein  DENV only, whole virus or envelope protein 
Assay serotype  DENV only, serotype tested and/or detected by assay 
Sample size  
Prevalence    
Incidence  
Response rate for risk of bias assessment (see ROB tables) 
Additional testing and 
comments  
includes secondary assays used for confirmatory testing, IgM 
or PCR prevalence, and comments regarding assay cross-
reactivity in the study or serotypes detected by assay 
animal species animal prevalence studies only 
mosquito species vector infection rate studies only 
infection rate vector infection rate studies only 
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S5 Figure Classification of populations identified through the systematic 
review: 
 
1. General population: these include seroprevalences studies among 
populations of individuals not suspected suspicion to have acute arbovirus 
infection at the time of the study. These populations include household 
members, blood donors, military personnel, students, and hospitalized patients 
and outpatients receiving care for other illnesses. 
 
2. Acute febrile illness (AFI): these include studies of undifferentiated febrile 
illness for which dengue, chikungunya, or yellow fever infection cannot be 
discerned on clinical grounds alone. In these studies, IgG prevalence 
measures drawn during the acute phase of illness are more likely to indicate 
previous infection with that pathogen rather than acute infection.  
 
3. Suspected dengue: these include cases in which dengue fever is suspected 
either by WHO-defined clinical criteria for probable dengue infection or when 
“suspected dengue” is stated as an inclusion criterion but is not further 
explained in the report. 
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S6 Figure Description of quality assessment criteria and studies’ risk of bias 
(ROB) appraisal. 
 
Description of quality assessment criteria and study risk of bias (ROB) 
appraisal for dengue (DENV), chikungunya (CHIKV), and yellow fever (YFV) 
virus human prevalence studies. 
 
The quality of CHIKV, DENV, and YFV human prevalence measures identified 
through our review was determined by assessing:  
 
1. The risk of bias (ROB) based on two quality domains 
a. The rigor of the sampling methodology 
b. The response rate 
 
2. The precision of the reported measures 
Studies were considered to have high precision if the number of 
individuals tested was  100. The 95% CI is 0.7-9.2% for a sample 
size of 100 with a prevalence of 5%, which is a reasonable 
precision.  
 
Study ROB appraisal 
 
1. Low ROB 
a. Probability-based sampling 
b. Response rate  80% 
 
2. High ROB 
a. Non-probability-based sampling 
b. Response rate < 80% 
 
3. Unclear ROB 
Studies with missing information for any of the domains were 
classified as having unclear ROB for that specific domain 
 
 
Note: 1) Prevalence measures among individuals presenting voluntarily to 
facilities where routine blood screening is conducted (i.e. blood donation 
center) were considered to have low ROB for the response rate domain. 
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S7 Figure Forest plot presenting the results of the meta-analysis of dengue 
virus prevalence measures among general populations in the Middle East and 
North Africa. 
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ABSTRACT 
 
The causes of infectious diarrhea among the migrant worker population in 
Qatar are not well understood. We conducted a prospective observational 
study to understand the demographic and clinical characteristics and 
infectious causes of diarrhea among migrant workers in Doha, Qatar. Seventy-
five male workers coming to the Qatar Red Crescent Worker’s Health Center 
outpatient clinic or emergency department were enrolled over a three-month 
period in 2015-2016. Epidemiologic surveys were administered to all subjects 
and the prevalence of 23 different stool pathogens was determined using 
multiplex PCR (FilmArray® Gastrointestinal PCR). A target pathogen was 
identified in 57% of subjects. Salmonella was the most prevalent pathogen 
and was detected in 27% of all subjects, followed by enteropathogenic E. coli 
(21%), enteroaggregative E. coli (15%) and enterotoxigenic E. coli (12%). Co-
detection of multiple pathogens was identified in 54% of positive stool 
samples. In an multivariable analysis, a triage heart rate ≥ 90 beats per minute 
was the only significant predictor of a positive PCR result (OR 4.5, 95% CI 1.1-
18.7). Use of multiplex PCR enabled the detection of gastrointestinal 
pathogens in a high proportion of cases, illustrating the utility of this diagnostic 
tool in epidemiologic studies of infectious diarrhea. 
 
INTRODUCTION 
 
Infectious diarrhea is an important cause of morbidity and mortality worldwide, 
resulting in considerable economic and public health burdens in both 
developed and developing countries [1-4]. In Qatar and the greater Gulf 
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region, few studies have been undertaken to characterize the epidemiology of 
infectious diarrhea [5, 6]. This is particularly the case among Qatar’s migrant 
worker population, over half a million of which are young and middle aged men 
from the Indian subcontinent and other Asian countries who have come to 
work in Qatar’s surging construction sector [7]. Many of these individuals live 
in populous labor camps with dormitory style housing which pose risk for 
transmission of communicable diseases, including gastrointestinal pathogens. 
Indeed, data from Qatar’s Ministry of Public Health suggest that a large 
proportion of the country’s annual foodborne disease outbreaks occur in this 
community (Farag, E.A., personal communication). Concerns have been 
raised over the possibility of underdetection of foodborne disease outbreaks in 
the migrant worker community and over the possibility of imported 
gastrointestinal pathogens. In addition, the unprecedented mass gathering 
anticipated during 2022 World Cup further motivates the need to understand 
the current epidemiology of diarrheal diseases in the country.  
 
Recently, multiplexed molecular diagnostics have become commercially 
available for the diagnosis of infectious diarrhea. These assays offer high 
sensitivity and specificity for a range of pathogens, providing a novel 
opportunity to narrow the diagnostic gap concerning the causes of infectious 
diarrhea [1, 8]. One such technology, the FilmArray® Gastrointestinal PCR is 
capable of detecting 23 different pathogens with a sensitivity ranging from 
94.5-100% and specificity from 97.1-100% depending on the target [9]. Such 
platforms are well suited for settings such as the migrant worker community in 
Qatar, for which broad diagnostic capacity near the point of care is currently 
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needed to facilitate actionable data concerning the causes of potential 
foodborne disease outbreaks [9, 10].  
  
Given the need for further data concerning the epidemiology of infectious 
diarrhea in the migrant worker population in Qatar, we conducted a 
prospective observational study aimed at describing the clinical features, 
epidemiologic characteristics, and etiologies of infectious diarrhea in this 
population using the FilmArray® Gastrointestinal PCR. 
 
MATERIALS AND METHODS 
 
Study site and ethical approval. This prospective, clinic-based study was 
conducted at the Qatar Red Crescent Workers Health Center (QRC), located 
in the New Industrial Area of Doha, Qatar. This facility provides outpatient and 
emergency department (ED) care exclusively to male migrant laborers, 
attending to 800 to 1,000 patients per day. This study was approved by the 
Institutional Review Board at Weill Cornell Medical College in Qatar (IRB #15-
00051). All study participants provided written, informed consent. 
 
Enrollment procedures and inclusion/exclusion criteria. From August-
September 2015 and January-March 2016, any individual coming to the clinic 
or ED with suspected infectious diarrhea was eligible to participate in the 
study. To be eligible for enrollment, subjects had to be ≥ 18 years of age and 
able to understand English, Arabic, Hindi, Malayalam, or Tagalog. These 
languages represented the majority of the clinic population and were based on 
the language capacity of the study personnel. For the study, presumptive 
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infectious diarrhea was defined as 3 or more loose stools in a 24-hour period 
or two loose stools in a 24-hour period accompanied by other gastrointestinal 
symptoms such as nausea, vomiting, abdominal cramps, tenesmus, bloody 
stools, or fever, which was defined as an oral temperature ≥ 38ºC [6, 11]. 
Subjects were excluded from the study if they were diagnosed with a non-
infectious cause of diarrhea, unable to provide a stool sample or complete the 
survey, or if the sample provided was not formed stool (i.e. did not conform to 
the shape of the collection container). Of note, subjects were asked to submit 
a stool sample for PCR testing regardless of whether stool culture or 
microscopy was ordered by the subject’s physician. We aimed to enroll 200 
subjects in order to detect a Salmonella prevalence of 5% with 95% 
confidence intervals of 2.4-9.0% [5, 9, 12]. 
 
Demographic/clinical data collection and microbiological analysis. A 
member of the study team administered a survey to enrolled subjects that 
assessed their demographic and clinical characteristics and a variety of risk 
factors for infectious diarrhea. The survey was an adaptation of the Minnesota 
Questionnaire, a standard foodborne disease outbreak case questionnaire 
(Appendix 2), and translated into the above study languages using a certified 
translation service (Language Scientific, Medford, MA, USA) [13]. Additional 
clinical and laboratory data (i.e. triage vital signs, medications prescribed, and 
pertinent laboratory results) were recorded retrospectively by accessing the 
patient’s medical record. These data were entered into a Research Electronic 
Data Capture (RedCap) database [14]. Stool samples were collected from 
study participants at the QRC clinic and immediately preserved in Cary-Blair 
enteric transport medium. The samples were then transported to Hamad 
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General Hospital Microbiology Laboratory in Doha, Qatar within 1-2 days, 
where they were tested with a commercially available multiplex PCR system, 
the FilmArray® Gastrointestinal Panel, (Biofire Diagnostics, Salt Lake City, UT, 
USA). The multiplex PCR was validated according to the manufacturer 
instructions prior to beginning the study. During the study, synthetic RNA 
quality controls were run for every 20 samples tested (Maine Molecular Quality 
Controls, Scarborough, ME, USA). Due to the time required to transport the 
specimens to the facility where they were tested, PCR results were typically 
reported to the subject’s physician within 2-4 days. Hence, treatment 
recommendations were made empirically by the subject’s physicians at the 
time of the visit.  
 
Statistical analyses. Associations between various demographic and clinical 
variables and the detection of any pathogen by PCR were summarized with 
odds ratios and 95% confidence intervals. Backward stepwise regression was 
used to construct a multivariable model to identify factors predictive of a 
positive PCR result for any pathogen. The following factors were included in 
the model: nationality, subjective fever, vomiting, temperature ≥38.5oC, heart 
rate ≥ 90 beats per minute, ≥6 stools in a 24-hour period, >5 fecal 
leukocytes/high-power field [16], ≥1 fecal red blood cell, and treatment in the 
emergency department. These factors were selected for conceptual reasons 
with a probability of removal from the model (Pr) set at 0.2. Data were 
analyzed in STATA 14.1 (StataCorp, College Station, TX). 
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RESULTS 
 
Enrollment. A total of 92 subjects were enrolled into the observational study. 
After enrollment, 17 subjects were excluded because they did not submit a 
stool sample (n=2), submitted formed stool (n=13), or submitted an insufficient 
quantity of stool for PCR testing (n=2). Thus, 75 subjects who completed the 
survey and submitted unformed stool were included in the analysis. 
 
Demographic characteristics. Table 2.1 summarizes the demographic 
characteristics of the study subjects. All subjects were male and the median 
age was 33 years. All subjects were migrants, most were from the Indian 
subcontinent, and 8% reported having returned to Qatar from their home 
country within 7 days of clinical presentation for diarrhea. Nearly all subjects 
were employed in construction-related fields and were living in dormitories 
within worker camps, each individual sharing a room and bathroom with a 
median of 5 other individuals.  
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Table 2.1 Demographic characteristics of study participants 
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Table 2.1 The demographic characteristics of the study participants. 
  
Characteristic n (%)* 
Median age (IQR) in years  33 (27-39) 
Male sex  75 (100) 
Country of origin  
  Nepal 24 (32.0) 
  India 20 (26.7) 
  Sri Lanka 12 (16.0) 
  Bangladesh 11 (14.7) 
  Philippines 5 (6.7) 
  Kenya 1 (1.3) 
  Ethiopia 1 (1.3) 
  Syria 1 (1.3) 
Type of work  
  construction 13 (17.3) 
  carpentery 11 (14.7) 
  plumber/pipefitter 8 (10.7) 
  metal worker/welder 8 (10.7) 
  electrician 7 (9.3) 
  painter 7 (9.3) 
  othera 21 (28) 
Shift time  
  day  72 (96) 
  night  2 (2.7) 
  not specified 1 (1.3) 
Dwelling   
  worker camp 72 (96) 
  private apartment 2 (2.7) 
  private house 1 (1.3) 
Number of roommates  
  1-3 17 (23.0) 
  4-6 31 (41.9) 
  7-10 24 (32.4) 
  11-13 2 (2.7) 
Shared bathroom 74 (98.7) 
International travel ≤ 7 days of presentation 6 (8.0)b   
*Data are reported as n (%) except where otherwise indicated 
IQR=interquartile range  
a Other work types include helper/cleaner (n=5), mason (n=3), 
machine operator (n=3), foreman (n=3), driver (n=2), store keeper 
(n=2), mechanic (n=1), chemical sprayer (n=1), insulation installer 
(n=1)  
b Countries traveled to include India (n=3), Bangladesh (n=2), Nepal 
(n=1) 
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Clinical characteristics. Table 2.2 summarizes the clinical characteristics of 
study participants. Overall, 24% of subjects were evaluated and treated in the 
emergency department. Two-thirds of individuals rated their baseline health as 
excellent or very good. Seven (9.4%) reported a medical co-morbidity, most 
frequently diabetes, and 4 (5.3%) reported a remote history of intra-abdominal 
surgery (appendectomy in all cases). No subjects were taking acid-
suppressive or immunosuppressive medications at the time of presentation, 
and 1.3% reported taking an antibiotic for any reason prior to developing 
diarrhea. The median duration of symptoms prior to clinical presentation was 2 
days, and 43% of subjects reported a maximum of ≥ 6 stools in a 24-hour 
period, a cutoff suggested as an indicator of severe diarrhea [15]. A total of 
29.8% of evaluable subjects had a heart rate ≥ 90 beats per minute and 10.6% 
had a temperature ≥ 38.5oC.  
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Table 2.2 Clinical characteristics of study participants. 
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Table 2.2 Clinical characteristics of study participants. 
 
Characteristic n (%)* 
Self-rated baseline health 
 
  Excellent 34 (45.3) 
  Very good 18 (24.0) 
  Good 14 (18.7) 
  Fair 7 (9.3) 
  Poor 2 (2.7) 
Current medical comorbidity 7 (9.4)a 
History of intra-abdominal surgery 4 (5.3%)b 
Antibiotic use prior to diarrheal illness (n=73)  
  yes 1 (1.3) 
  no  69 (94.6) 
  unknown 3 (4.1) 
Contact with another person with diarrheal illness 3 (4.0) 
Acid-suppressive or immunosuppressive medication use 0 (0) 
Location of treatment 
 
  clinic 57 (76.0) 
  emergency department 18 (24.0) 
Median duration of symptoms (IQR) in days 2 (1-3) 
Symptoms 
 
  diarrhea 75 (100.0) 
  abdominal cramps 59 (78.7) 
  fatigue 59 (78.6) 
  fever 37 (49.3) 
  chills 32 (42.7) 
  headache 34 (45.3) 
  body aches 34 (45.3) 
  nausea 22 (29.3) 
  vomiting 19 (25.3) 
  bloody diarrhea 2 (2.7) 
≥6 stools per day (n=74) 32 (43.2) 
Temperature ≥ 38.5oC (n=65) 5 (7.7) 
Heart rate ≥ 90 beats per minute (n=47) 17 (29.8) 
Systolic blood pressure < 90 mmHg (n=35) 0 
*Data are reported as n (%) except where otherwise indicated 
IQR=interquartile range 
a Medical comorbidity includes diabetes (n=4), hyperlipidemia (n=1); arthritis 
(n=1), hypertension (n=2) 
b All had undergone appendectomy years prior to presentation  
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Laboratory and Stool PCR Results. Table 2.3 summarizes the available 
laboratory data. Complete blood counts were performed in 11 subjects, of 
whom 4 (36.6%) had white blood cell counts ≥ 15,000 per mm3. No subjects 
had low hematocrit or platelet values. Stool microscopy was performed in all 
subjects. One or more fecal leukocytes were present in 94.2% of all stool 
samples and Entamoeba sp. was identified in 15.3% of all samples by 
microscopy. Stool culture was ordered for 5 subjects and was negative in all 
cases. Figure 2.1 depicts the prevalence of pathogens detected by multiplex 
PCR. Overall, one or more pathogens was identified in 57% of samples. 
Salmonella sp. was the most prevalent pathogen and was identified in 27% of 
samples. Diarrheagenic E. coli strains were also prevalent, including 
Enteropathogenic E. coli (EPEC) in 21%, Enteroaggregative E. coli (EAEC) in 
15%, and Enterotoxigenic E. coli (ETEC) in 12% of samples. Norovirus was 
identified in 5% of samples and Clostridium difficile was not identified in any 
samples. Two or more PCR targets were detected in 53% of positive samples 
(Table 2.3). Co-detections occurred for the majority of all pathogens with the 
exception of Salmonella, for which co-detection of multiple pathogens was 
identified in 35% of samples (Figure 2.1). The presence of a heart rate ≥ 90 
beats per minute was the only significant predictor of a positive PCR result in 
the univariate analysis. This covariate remained a significant predictor (OR 
4.5, 95% CI 1.1-18.7) when adjusted for the aforementioned covariates in the 
stepwise multivariable analysis. 
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Table 2.3 Laboratory and microbiology test results of study participants. 
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Table 2.3 Laboratory and microbiology test results of study participants. 
 
Characteristic  n (%) 
Blood count (n=11)  
  white blood cells ≥15,000 per mm3 (n=11) 4 (36.6) 
  hematocrit < 40% 0 (0) 
  platelet <150,000 per microliter 0 (0) 
Stool microscopic exam (n=52)  
  fecal leukocytes present 49 (94.2) 
  >5 leukocytes/high-power field 36 (69.2) 
  red blood cells present 16 (30.7) 
  Entamoeba sp.  8 (15.3) 
  Giardia lamblia 1 (1.9) 
  Enterobius vermicularis 1 (1.9) 
  Ascaris lumbricoides  1 (1.9) 
  hookworm 1 (1.9) 
Stool culture for Salmonella/Shigella (n=5)  
  negative 5 (100.0) 
FilmArray® Gastrointestinal PCR (n=75)  
  negative 32 (42.7) 
  positive 43 (57.3) 
Pathogen Frequency  
  Salmonella 20 (46.5) 
  Enteropathogenic E. coli (EPEC) 16 (37.2) 
  Enteroaggregative E. coli (EAEC) 11 (25.6) 
  Enterotoxigenic E. coli (ETEC) lt/st 9 (20.9) 
  Shigella/Enteroinvasive E. coli (EIEC) 6 (13.9) 
  Campylobacter 6 (13.9) 
  Giardia lambda 6 (13.9) 
  Shiga-like toxin-producing E. coli (STEC) stx1/stx2 4 (9.3) 
  Norovirus 4 (9.3) 
  Rotavirus A 2 (4.7) 
  Astrovirus 1 (2.3) 
  Plesiomonas shigelloides 1 (2.3) 
  E.coli 0157 1 (2.3) 
Number of pathogens per positive sample (n=43)  
 
  1  20 (46.5) 
  2  12 (27.9) 
  3  5 (11.7) 
  4  4 (9.3) 
  5  1 (2.3) 
  6 0 (0) 
  7  1 (2.3) 
Received antibiotic (n=66) 36 (65.4) 
  metronidazole 27 (43.6) 
  ciprofloxacin  24 (38.1) 
  ciprofloxacin + metronidazole 9 (13.6) 
  trimethoprim-sulfamethoxazole 2 (3.0) 
Received IV fluids (n=55) 12 (18.8) 
Discharged from clinic or emergency department 71 (94.7) 
Hospitalized 2 (3.0) 
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Figure 2.1 Frequency of pathogen detection by multiplex PCR and frequency 
of detection in samples with ≥ 2 pathogens. 
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Treatment and outcome. A total of 65% of evaluable subjects received an 
antibiotic, most commonly metronidazole (43%), ciprofloxacin (38%) or both in 
combination (13%) (Table 2.3). An antibiotic was prescribed in 15% of those 
for whom PCR was negative for all pathogens. Moreover, 5 (27%) of 
individuals who received ciprofloxacin did not have any potentially susceptible 
bacterial pathogen detected by PCR (i.e. Campylobacter, Salmonella, 
Shigella, or any E. coli), and among those prescribed metronidazole, 
Entamoeba histolytica or Giardia lamblia was not detected in 85% (18 of 21 
cases) (Table 2.4). A total of 3% of subjects were hospitalized for continued 
treatment directly after initial treatment at the study center. 
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Table 2.4 Prevalence of various demographic and clinical characteristics  
in patients with positive and negative multiplex PCR results. 
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Table 2.4 Prevalence of various demographic and clinical characteristics in 
patients with positive and negative multiplex PCR results. 
 
Variable 
Positive 
PCR 
n (%) (n=43) 
Negative 
PCR 
n (%) (n=32) 
OR (95% CI) 
Demographic    
Country     
  India 14 (32.6) 6 (18.8) 2.0 (0.6-7.5) 
  Nepal 12 (27.9) 12 (37.5) 0.6 (0.2-1.9) 
  Bangladesh 5 (11.6) 6 (18.8) 0.5 (0.1-2.5) 
  Philippines 3 (7.0) 2 (6.3) 0.3 (0.04-1.7) 
  Sri Lanka 8 (18.6) 4 (12.5) 1.6 (0.3-7.9) 
International travel ≤ 7 days of 
presentation 
4 (9.3) 2 (6.3) 1.5 (0.2-17.9) 
living with ≥ 6 roommates 17 (39.5) 9 (28.1) 1.7 (0.5-5.3) 
Meal location     
  home 27 (62.8) 22 (68.8) 0.7 (0.2-2.2) 
  workplace cafeteria 4 (9.3) 1 (3.1) 3.1 (0.2-161.5) 
  catering company 7 (16.3) 9 (28.1) 0.4 (0.1-1.7) 
cooking stove in home 33 (76.7) 20 (62.5) 1.8 (0.5-5.7) 
refrigerator in home 23 (53.5) 16 (50.0) 1.1 (0.4-3.0) 
Clinical    
Location of treatment    
  emergency department 12 (27.9) 6 (18.8) 1.6 (0.4-6.2) 
Symptom duration ≤ 1 day 32 (74.4) 20 (62.5) 1.4 (0.4-4.5) 
Symptoms    
  abdominal cramps 36 (83.7) 23 (71.9) 2.0 (0.5-7.2) 
  fatigue 33 (76.7) 26 (81.2) 0.76 (0.2-2.6) 
  fever 19 (44.1) 19 (59.3) 0.5 (0.1-1.5) 
  chills 20 (46.5) 12 (37.5) 1.4 (0.5-4.1) 
  headache 23 (53.5) 11 (34.3) 2.1 (0.7-6.3) 
  body aches 23 (53.5) 11 (34.3) 2.1 (0.7-6.3) 
  nausea 16 (37.2) 6 (18.8) 2.5 (0.6-9.1) 
  vomiting 14 (32.6) 5 (15.6) 2.6 (0.7-10.4) 
  bloody diarrhea 2 (4.7) 0 (0) NC 
≥6 stools per day (n=74) 21 (50.0) 11 (34.3) 1.9 (0.6-5.5) 
Temperature ≥ 38.5oC (n=47) 3 (11.1) 2 (10.0) 1.1 (0.1-0.6) 
Heart rate ≥ 90 beats per minute (n=57) 14 (41.1) 3 (13.0) 4.6 (1.0-28.4)* 
Laboratory data (n=64)    
> 5 stool leukocytes 14 (37.8) 11 (40.7) 0.8 (0.2-2.7) 
≥ 1 stool red blood cell 14 (37.8) 10 (37.0) 1.0 (0.3-3.4) 
Treatment (n=66)    
  receipt of any empiric antimicrobial 28 (73.6) 16 (57.1) 2.1 (0.6-6.8) 
* indicates significant association 
Abbreviations: CI, confidence interval; NC, not calculated; OR, odds ratio; PCR polymerase 
chain reaction 
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DISCUSSION 
 
Our study offers a detailed picture of the epidemiology of infectious diarrhea in 
the migrant worker population in Qatar. We found that Salmonella accounts for 
a high proportion of diarrhea cases, followed by the diarrheagenic E. coli 
pathotypes EPEC, EAEC, and ETEC. Most of these infections would not have 
been ascertained under the present clinical and laboratory practices at the 
study site. In addition, the high overall pathogen detection rate of 57% in our 
study demonstrates the utility of multiplex PCR in epidemiologic surveillance 
studies and its potential to influence antibiotic prescribing practices for 
diarrheal diseases.  
 
In many settings, the etiologies of diarrheal diseases remain poorly 
characterized due to limited surveillance and the low detection rates of 
traditional pathogen identification methods [1, 2, 17]. In our study using 
multiplex PCR, 11 different pathogens were identified with an overall detection 
rate of 57%. This detection rate exceeds traditional laboratory detection 
methods [2] and compares favorably to prior studies utilizing the FilmArray® 
PCR in which detection rates ranged from 33-53% [9, 12, 18]. Thus, the 
breadth of pathogens surveyed and ease of use of this PCR platform make it 
well suited for epidemiologic studies, particularly in settings such as ours in 
which the traditional suite of culture media types, immunoassays and uniplex 
PCR protocols used to survey a similarly broad range of pathogens would be 
difficult to implement due to limited human and laboratory resources.  
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Another notable finding in our study was the 27% prevalence of Salmonella 
encountered in the study cohort. This prevalence exceeds those reported from 
cohorts of similar ages in Qatar [5] and elsewhere [9, 12, 17, 19, 20], where 
Salmonella prevalence ranged from 2-10% in both PCR and culture-based 
studies. Nontyphoidal Salmonella is recognized as a major bacterial cause of 
infectious diarrhea and the most common bacterial cause of foodborne 
outbreaks, but its incidence has declined over recent years in both Europe [21] 
and the United States [22]. In our study, whether the Salmonella cases were 
sporadic or outbreak-related could not be determined given the absence of 
culture isolates for most cases. However, the temporal pattern and the diverse 
demographic characteristics of Salmonella cases suggested that these cases 
were sporadic. Nevertheless, this finding warrants further research to clarify 
the epidemiology and risk factors for Salmonella infections in the migrant 
worker population and to evaluate to need for targeted prevention measures.  
 
Diarrheagenic E. coli pathotypes were also commonly detected in our study 
population. This finding is consistent with prior surveillance studies utilizing 
multiplex PCR [9, 12, 23]. Unlike studies in other settings, however, ours 
detected a relatively low frequency of norovirus and no cases of C. difficile. 
Our study definition may have influenced this finding, as not including vomiting 
as a standalone inclusion criterion may have reduced the number of norovirus 
cases we were able to enroll. The absence of C. difficile is not unexpected 
given the study population of predominantly young, healthy adults with limited 
prior antibiotic exposure or contact with healthcare environments where C. 
difficile is prevalent.   
 
 117 
In our study, two or more pathogens were identified in 53% of positive 
samples and co-detections were present in the majority of pathogens detected 
except for Salmonella (Figure 2.2). The high frequency of co-detection for 
EPEC, ETEC, and EAEC is consistent with prior studies [12, 18]. Still, co-
detections were reported in 16-31% of positive samples in prior studies using 
the FilmArray® PCR [9, 12, 18], all of which exceeded the co-detection rates of 
routine comparator methods. Whether stools containing multiple pathogens 
represent true co-infections or transient colonizers is unclear [15]. 
Nevertheless, the identification of multiple-pathogen-containing stool 
specimens will likely become more common with the broader clinical use of 
highly multiplexed molecular diagnostics. The high co-detection rate in our 
study also raises the potential importance of investigating the role of co-
pathogens in future studies of pathogen-specific enteric gastrointestinal 
infections.  
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Figure 2.2 Results of multiplex PCR testing for positive stool samples 
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The univariate analysis of multiple demographic, clinical, and laboratory 
characteristics identified none that were predictive of a positive PCR result 
except for having a heart rate ≥ 90 beats per minute, which is likely a marker 
of dehydration cause by more severe diarrhea (Table 2.4). The precision of 
this estimate was low, however, and our small sample size limited power to 
detect significant effects in this analysis. Still, refining diagnostic algorithms for 
stool testing remains an important endeavor given the low positivity rate of 
traditional methods and the high cost of PCR testing [2, 24]. The presence of 
fecal leukocytes, for example, is often used to indicate an inflammatory 
process that suggests the presence of an invasive pathogen. However, neither 
the presence of fecal leukocytes nor threshold quantities greater than five cells 
per high-power field significantly increased the odds of detecting a pathogen 
by multiplex PCR in our study. The presence of fecal leukocytes is known to 
lack sensitivity since many forms of colitis occur focally [15, 16]. However, this 
lack of association may also reflect the high sensitivity of the PCR assay in 
detecting low microbe burdens. 
 
Finally, the high proportion of subjects who received empiric antibiotics raises 
the potential for broadly multiplex PCR to influence antibiotic use for infectious 
diarrhea. Usually, empiric antibiotics for infectious diarrhea should be reserved 
for febrile dysentery or suspected systemic infection, severe travelers’ 
diarrhea, or healthcare associated diarrhea suspected to be caused by 
Clostridium difficile [2, 15, 25]. In our study population of predominantly 
healthy young men without immune compromising conditions, 65% were 
empirically prescribed an antibiotic, most commonly ciprofloxacin and/or 
metronidazole. Receipt of either of these medications was not associated with 
 121 
having a PCR result positive for any of the organisms for which these 
antibiotics have activity. Quinolone resistance has been documented in over 
50% of Campylobacter isolates in Qatar [26] and other Gulf countries [27], and 
the effect of antibiotic treatment in prolonging the carrier state for nontyphoidal 
Salmonella may be particularly detrimental among our study population given 
the augmented risk of person-to-person transmission in dormitory settings.  
 
Our study has certain strengths and limitations. The prospective approach of 
our study allowed us to ensure that all patients clinically diagnosed infectious 
diarrhea were offered the opportunity to enroll in the study and that formed 
stools were excluded from PCR testing. Retrospective studies are limited by 
these elements, as the likelihood of stool testing is known to vary among 
physicians regardless of patient characteristics [2], and laboratory protocols for 
stool testing may not always be strictly enforced. Various factors may have 
influenced the frequencies of the microbes detected in our study, including our 
chosen case definition, seasonal variation in the incidence of certain 
pathogens [26], and the unique study setting and population. Transportation to 
the study clinic may have also been a barrier for some migrant workers, which 
may have biased the pathogen distribution against those that cause more mild 
illness [17]. Due to an administrative issue, enrollment into our study was 
suspended for 19 weeks, which precluded us from reaching our planned 
sample size.  Consequently, the precision of our estimates of the prevalence 
of the various pathogens was less than anticipated and we were likely 
underpowered to detect associations with putative risk factors. For logistical 
reasons, our study did not include a control group, which would have enabled 
us to compare the frequency of detection of pathogens, particularly the 
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diarrheagenic E. coli pathotypes, in asymptomatic persons and those with 
diarrhea. We also did not compare the performance of the FilmArray® PCR to 
traditional stool diagnostic methods such as culture, enzyme immunoassay 
(EIA), or uniplex PCR. Such studies have been published previously, however, 
and demonstrate that the FilmArray® PCR has high sensitivity and specificity 
in comparison to traditional methods [9, 18]. Still, the limited clinical use of 
stool cultures in our study precluded the determination of antibiotic 
susceptibility profiles and strain typing for Salmonella and other pathogens. 
Finally, although our survey was modified from the validated Minnesota 
Questionnaire with the input of key stakeholders at the study clinic and the 
Qatar Ministry of Public Health, the survey was not validated prior to being 
implemented for the study.  
 
In summary, use of multiplex PCR enabled the detection of one or more 
pathogens in 57% of cases of infectious diarrhea among the migrant worker 
population in Qatar, with Salmonella and diarrheagenic E. coli the most 
commonly identified pathogens. Our study illustrates the utility of this 
diagnostic platform in epidemiologic studies and serves as a foundation for 
future research to understand the epidemiology and risk factors for infectious 
diarrhea among the migrant worker population. Further research is needed to 
understand the optimal use and interpretation of the FilmArray® PCR in the 
diagnosis of infectious diarrhea. 
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Research Questionnaire           Study ID # __________ 
 1 
Research Questionnaire 
 
Title: The Causes and Risk factors for Diarrhea    
among Migrant Workers in Qatar 
 
Initial Screening Question: 
 
Do you think you will be able to submit a sample of your stool today for the 
research study? 
    £   If Yes à CONTINUE with survey after stool sample is       
                                                 received 
 
    £  If No à STOP HERE / Do NOT continue with survey 
   
Basic Information:   
 
Study ID: ________ 
 
Date of interview  ___ / ___ / ______ 
Interviewer name: ___________________ 
Language of interview:  £ Arabic £ English £ Filipino    
     £ Hindi  £ Nepali £ Urdu  
 
Location of treatment:    £ clinic  £ emergency room 
 
Section I. Demographics 
 
*Please remember that you may choose not to answer questions 
that you feel are too personal or uncomfortable for you. 
 
1. Age:  ________ years 
 
2. Gender:  £ Male £ Female                     
 
3. What country are you from?  £ Bangladesh  £ Egypt £ India  
     £ Nepal   £ Pakistan £ Philippines 
     £ Qatar  £ Sudan  £ Sri Lanka 
     £ Other _________________ 
 
4. Have you visited any other country during the past 21 days? Y N 
a. If yes, which country?  _____________________  
 
5. What is the name of the company you work for? _____________________________   
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 2 
 
6. What work do you do for this company? (be as specific as possible):  
  £ construction worker    £ driver 
  £ metal worker      £ guard 
  £ crane / heavy equipment operator   £ plumber 
  £ other __________________________ 
 
7. When do you usually work?  £ Day shift    
£ Night shift  
 
8. What type of place do you live in? 
   £ worker camp (apartment or dormitory) 
   £ private apartment  
   £ private house 
 
9. Do other people live in the same room with you?   Y N 
a. If yes, how many other people? ______________  
 
10. What type of bathroom do you use at home? 
   £ private 
   £ shared with other people 
 
 
 
1. Which did you experience first:     £ vomit    £ diarrhea 
 
2. Date of onset of vomit or diarrhea (whichever occurred first): ____ / ____ / ____   
 
1  am 7  am  13-1 pm 19-7  pm  
2  8   14-2  20-8 
3  9  15-3  21-9     
4  10  16-4  22-10 
5  11  17-5  23-11 
6  am 12 noon  18-6 pm 24-12 midnight 
 
3. Where were you when your symptoms began? £ home    £ work     £ other  
 
4. Time of last episode of vomit or diarrhea:  ____:____ AM PM  
Did you have:   
Nausea   Y  N  Do not Know (DK)  
Vomiting   Y  N  DK   
Diarrhea    Y  N  DK 
1. If yes:   Maximum number of stools in a 24-hour period: _________ 
 
Bloody diarrhea  Y  N  DK   
Abdominal cramps Y  N  DK   
Section II.  History of Present Illness  
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Fever    Y  N  DK 
Chills   Y  N  DK   
Headache  Y  N  DK   
Body aches  Y  N  DK 
Fatigue   Y  N  DK   
Constipation  Y  N  DK   
Other:_________ Y  N   DK 
 
5. Did you take any medications (including traditional medicines or home remedies) for 
your current illness before you came to the clinic today?  
  Y  N 
a. If yes, what are the names of the medications? 
1. ________________________________  
2. ________________________________  
 
6. Did you attend another health center before coming to the Red Crescent clinic 
today?    
    Y    N 
     a. If yes, which one:  
a. £ pharmacy  Date ___ / ___ / ______  
b. £ clinic  Date ___ / ___ / ______ 
c. £ hospital  Date ___ / ___ / ______ 
    b. what treatment were you given? _______________________________ 
7. Were you prescribed an antibiotic for any reason, prior to your current illness? 
    Y  N  DK 
a. If yes, which one?   
1. ________________________________  
 
8. Do you know of anyone else with a similar illness during the past week?  
       Y    N    DK 
a. If yes, how many other people? _________ 
b. Have you had direct contact with any of those people?   
     Y      N       DK 
c. What activities did you share with those people during the past week? 
(check all that apply)   
 £ Sleep in the same room   £ Eat in the same cafeteria 
 £ Share the same bathroom  £ Cook together 
 £ Work for the same company £ Share food from a common plate 
 £ Work at the same site 
 
9. Did you have to miss work because of your illness?    Y N  
a. If yes, how many hours? _________________ 
 
10. Have you eaten any foods or drunk any beverages that you think could have caused 
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you to become ill?  Y  N  DK 
a. If yes, please describe food or drink and the date/time you had it: 
___________________________________________________________
___________________________________________________________   
 
11. Do you think you became ill from contact with someone else who was ill before you? 
    Y  N  DK 
a. If yes, please describe when and where you contacted this person (do not 
use his or her name): 
___________________________________________________________
___________________________________________________________  
 
 
1. How would you describe your health normally?        
  £ Excellent    £ Very good  £ Good  £ Fair   £ Poor 
 
2. Do you have any medical problems?   Y  N        DK 
 £ Diabetes   £ Heart disease  
 £ Asthma    £ Cancer (type ________________)  
 £ lung disease (type____________)  £ Liver disease (type ___________) 
 £ High blood pressure   £ Other:_____________________  
 £ Kidney disease    £ Other:_____________________ 
 £ Anemia   £ Other:_____________________ 
    
 
3. What medications do you take on a regular basis? 
a. ___________________________  
b. ___________________________  
c. ___________________________  
d. ___________________________  
e. ___________________________  
 
4. Have you ever had surgery in your life?   Y  N  DK 
a. If yes, what surgeries did you have? 
1. ___________________________  
2. ___________________________  
3. ___________________________  
 
5. Are you currently a smoker?     Y        N   
 
6. How many times over the past 6 months have you developed a diarrheal illness? 
 
   £ 0 times   £ 1-2 times  £ 3-4 times   £ 5-6 times  £ > 5 times  
 
 
Section III.  Medical History 
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1. Did you travel anywhere during the week before your illness began?       Y      N 
a. If yes, where?  ___________________ 
    Dates  ____ / ____ / ____  to ____ / ____ / ____  
  
2. From what sources of water did you drink during the week before your illness 
began? 
  City tap water    Y  N  DK 
  Private well water   Y  N  DK 
  Untreated surface water  
   (river, pond, lake)  Y  N  DK 
  Bottled water     Y  N  DK 
  Other ___________________ 
 
3. Where do you usually eat the following meals? (check one box for each meal type) 
 
Place                               Meal  
             Breakfast    Lunch   Dinner 
I do not usually eat this meal:       £         £      £ 
food I prepare at home:         £         £      £ 
food prepared by my roommate:       £         £      £ 
food prepared by my co-worker:      £         £      £ 
 (who I do not live with) 
workplace cafeteria:          £         £      £ 
catering company:           £         £      £ 
restaurant:            £         £      £ 
Other: __________________        £         £      £ 
 
4. Do you have a stove that works in your home?    Y  N 
 
5. Do you have a refrigerator that works in your home? Y  N 
 
6. Do you cook for other people in your home?    Y  N 
 
a. What foods do you typically cook? 
___________________________________________________________  
 
7. How often do you wash your hands before you eat?  
 £ always  £ very often   £ sometimes   £ not very often       £ never 
 
8. How often do you wash your hands before you cook?  
 £ always  £ very often   £ sometimes   £ not very often       £ never 
 
9. Do you drink unpasteurized (also called raw) milk or eat cheeses made with 
unpasteurized milk?  
Section IV. Exposure History 
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